Anti-epileptic drugs in migraine prevention

Headache and Pain: Diagnostic Challenges, Current Therapy

Volumn 16, Issue 1, 2005, Pages 18-36

  Peterlin, B Lee ^a   Ward, Thomas N ^b   Levin, Morris ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Department of Medicine ^*

Author keywords

Antiepileptic drugs; Carbamazepine; Divalproex sodium; Gabapentin; Lamotrigine; Levetiracetam; Migraine prophylaxis; Oxcarbazepine; Tiagabine; Topiramate; Zonisamide

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; CORTICOSTEROID; DIAZEPAM; DILTIAZEM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; WARFARIN; ZONISAMIDE;

AGITATION; AGRANULOCYTOSIS; ALOPECIA; ANOREXIA; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRY EYE; DYSPEPSIA; DYSPHORIA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMICRANIA CONTINUA; HUMAN; HYPERTHERMIA; HYPESTHESIA; HYPONATREMIA; INFECTION; LEUKOPENIA; MEMORY DISORDER; MENTAL INSTABILITY; MIGRAINE; MIGRAINE WITH AURA; MOTOR DYSFUNCTION; NAUSEA; NEPHROLITHIASIS; NEURAL TUBE DEFECT; OROFACIAL DYSKINESIA; PAIN; PARESTHESIA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RASH; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; STONE FORMATION; SUNCT SYNDROME; TASTE DISORDER; TIC; TOXIC HEPATITIS; TREMOR; VISUAL DISORDER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 28244469265     PISSN: 15458261     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257-270.
2. Brandes JL. Treatment approaches to maximizing therapeutic response in migraine. Neurology. 2003;61(suppl 4):S21-S26.
3. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: results from the American Migraine Study II. Headache. 2001;41:646-657.
4. Silberstein SD, Lipton RB, Goadsby PJ, eds. Migraine: diagnosis and treatment. In: Headache in Clinical Practice. 2nd ed. London: Martin Dunitz Ltd; 2002:69-112.
5. Cutrer FM. Antiepileptic drugs: how they work in headache. Headache. 2001;41(suppl 1):S3-S10.
6. Lipton RB, Ottman R, Ehrenberg BL, Hauser WA. Comorbidity of migraine: the connection between migraine and epilepsy. Neurology. 1994;44(suppl 7):S28-S32.
7. Andermann F, Andermann FA. Migraine-epilepsy relationships; epidemiological and genetic aspects. In: Andermann FA, Lugaresi E, eds. Migraine and Epilepsy. Boston: Butterworths; 1987:281-291.
8. Friedenberg S, Dodick DW. Migraine-associated seizure: a case of reversible MRI abnormalities and persistent nondominant hemisphere syndrome. Headache. 2000;40:487-490.
9. Bradley WG, ed. Neurology in Clinical Practice: The Neurological Disorders. Vol 2. 3rd ed. Boston: Butterworth-Heinemann; 2000.
10. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40 (suppl 5):S2-S10.
11. Pappagallo M. Newer antiepileptic drugs. Possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003;25:2506-2538.
12. Mathew NT. Antiepileptic drugs in migraine prevention. Headache. 2001;41(suppl 1):S18-S24.
13. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997;17:93-100.
14. Silberstein SD. Divalproex sodium in headache-literature review and clinical guidelines. Headache. 1996;36:547-555.
15. Wheeler SD. Antiepileptic drug therapy in migraine headache. Curr Treat Options Neurol. 2002;4:383-394.
16. Freitag FG, Collins SD, Carlson HA, et al, for the Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652-1659.
17. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988;78:346-348.
18. Agostoni E, Frigerio R, Santoro P. Antiepileptic drugs in the treatment of chronic headaches. Neurol Sci. 2003;24(suppl 2): S128-S131.
19. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81-84.
20. Jensen R, Brinck T, Olesen J. Sodium valproate has prophylactic in migraine without aura: a triple-blind, placebo-controlled cross-over study. Neurology. 1994;44:647-651.
21. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103-108.
22. Silberstein SD, Collins SD; Long-term Safety of Depakote in Headache Prophylaxis Study Group. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Headache. 1999;39:633-643.
23. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
24. Thomas JR. The long-term safety of divalproex sodium prophylactic treatment of patients with migraine. Proceedings of the 7th International Headache Congress; September 16-20, 1995, Toronto, Ontario. Cephalalgia. 1995;15(suppl 14):266.
25. Glauser TA. Topiramate. Epilepsia. 1999;40(suppl 5):S71-S80.
26. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thomson Healthcare; 2004: 2484-2490.
27. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291: 965-973.
28. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490-495.
29. Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache. 2002;42:804-809.
30. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind, randomized, placebo-controlled study of topiramate in the prophylactic treatment of migraine with and without aura. Cephalalgia. 2000;20:305. Abstract.
31. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41:968-975.
32. Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache. 2002;42:796-803.
33. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1261-1273.
34. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium. Headache. 2002;42:85.
35. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119-128.
36. LaRoche SM, Helmers DL. The new antiepileptic drugs: scientific review. JAMA. 2004;291:605-614.
37. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thomson Healthcare; 2004: 2559-2565.
38. Fisher RS, Sachdeo RC, Pellock J, et al. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology. 2001;56:743-748.
39. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter. 2000;151:145-148.
40. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thomson Healthcare; 2004: 1537-1544.
41. Bourgeois BF. New antiepileptic drugs. Arch Neurol. 1998;55:1181-1183.
42. Steiner TJ, Findley LJ, Yeun AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17:109-112.
43. Vajda FJ. New antiepileptic drugs. J Clin Neurosci. 2000;7:88-101.
44. D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia. 1999;19:64-66.
45. Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura-a pilot study. Cephalalgia. 1999;19:58-63.
46. Wheeler SD. Lamotrigine efficacy in migraine prevention. Cephalalgia. 2001;21:374. Abstract.
47. Pascual J, Caminero AB, Valentin M, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache. 2004;44: 1024-1028.
48. Chen WT, Fuh JL, Lu SR, Wang SJ. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache. 2001;41:823-825.
49. D'Andrea G, Bonavita V, Rigamonti A, Bussone G. Treatment of migraine with aura: comments and perspectives. Neurol Sci. 2003;23:271-278.
50. D'Andrea G, Granella F, Ghiotto N, Nappi G. Lamotrigine in the treatment of SUNCT syndrome. Neurology. 2001;57:1723-1725.
51. Drake ME, Greathouse NI, Armentbright AD, Renner JB. Preventive treatment of migraine with zonisamide. Cephalalgia. 2001;21:374. Abstract.
52. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ. New migraine preventive options: an update with pathophysiological considerations. Rev Hosp Clin Fac Med S Paulo. 2002;57:293-298.
53. Krusz JC. Zonisamide in the treatment of headache disorders. Cephalalgia. 2001;21: 374-375. Abstract.
54. Nash EM, Sangha KS. Levetiracetam. Am J Health Syst Pharm. 2001;58:1195-1199.
55. Cochran JW. Levetiracetam as migraine prophylaxis. Clin J Pain. 2004;20:198-199.
56. Drake ME, Greathouse NI, Armentbright AD, Renner JB. Levetiracetam for preventative treatment of migraine. Cephalalgia. 2001;21:373. Abstract.
57. Krusz JC. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia. 2001;21: 373. Abstract.
58. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004;44:238-243.
59. Drake ME Jr, Kay AM, Knapp MS, Greathouse NI. An open-label trial of tiagabine for migraine prophylaxis. Headache. 1999;39:352. Abstract.
60. Freitag FG, Diamond S, Diamond ML, et al. The prophylaxis of migraine with the gabaagonist, tiagabine: a clinical report. Headache. 1999;39:354. Abstract.
61. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334:168-175.
62. Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci. 2004;25(suppl 3):S161-S166.
63. Arroyo S, Sander JW. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology. 1999;53:1170-1174.
64. Rompel H, Bauermeister BA. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J. 1970;24:75-80.
65. Anthony M, Lance JW, Somerville B. A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine. Med J Aust. 1972;1:1343-1346.
66. Krusz JC. Carbamazepine, controlled-release, is effective in reducing chronic headaches. Cephalalgia. 2000;20:422. Abstract.
67. Kalis MM, Huff NA. Oxcarbazepine, an epileptic agent. Clin Ther. 2001;23:680-700.
68. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thomson; 2004: 2324-2328.
69. Krusz JC. Oxcarbazepine is effective in chronic migraine prophylaxis. Cephalalgia. 2000;20:425. Abstract.
70. Tfelt-Hansen P, Block G, Dahlof C, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765-786.